
Emilie Thivat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/877101/publications.pdf Version: 2024-02-01



EMILIE THIMAT

#	Article	IF	CITATIONS
1	The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology, 2016, 90, 69-78.	0.9	109
2	Quality of life after mastectomy with or without immediate breast reconstruction. British Journal of Surgery, 2017, 104, 1197-1206.	0.1	105
3	Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer, 2010, 10, 648.	1.1	97
4	Temozolomide and unusual indications: Review of literature. Cancer Treatment Reviews, 2013, 39, 125-135.	3.4	71
5	Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncology Letters, 2016, 12, 1223-1232.	0.8	64
6	Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Oncologist, 2008, 13, 1235-1245.	1.9	56
7	Importance of metabolic changes induced by chemotherapy on prognosis of earlyâ€stage breast cancer patients: a review of potential mechanisms. Obesity Reviews, 2012, 13, 368-380.	3.1	48
8	Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study. Oncology, 2010, 78, 205-209.	0.9	46
9	Optimal Methionine-Free Diet Duration for Nitrourea Treatment: A Phase I Clinical Trial. Nutrition and Cancer, 2007, 60, 23-30.	0.9	44
10	Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancer. Surgical Oncology, 2009, 18, 357-365.	0.8	43
11	A New Prognostic Classification After Primary Chemotherapy for Breast Cancer: Residual Disease in Breast and Nodes (RDBN). Cancer Journal (Sudbury, Mass), 2008, 14, 128-132.	1.0	35
12	Hibernoma: A Clinical Model for Exploring the Role of Brown Adipose Tissue in the Regulation of Body Weight?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1-6.	1.8	28
13	Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. Medicine (United States), 2018, 97, e13676.	0.4	28
14	Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity. Oncology, 2019, 96, 223-234.	0.9	27
15	Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in firstâ€line treatment of metastatic castrationâ€resistant prostate cancer. Cancer Medicine, 2021, 10, 2332-2340.	1.3	24
16	A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Research, 2007, 27, 2779-83.	0.5	23
17	Temozolomide Treatment of an Adult with a Relapsing Medulloblastoma. Cancer Investigation, 2007, 25, 470-475.	0.6	21
18	Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?. Cancer Investigation, 2009, 27, 81-85.	0.6	20

Emilie Thivat

#	Article	IF	CITATIONS
19	Late lines of treatment benefit survival in metastatic breast cancer in current practice?. Breast, 2011, 20, 574-578.	0.9	20
20	Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors. Oncology, 2013, 84, 67-74.	0.9	18
21	Neutrophils are immune cells preferentially targeted by retinoic acid in elderly subjects. Immunity and Ageing, 2010, 7, 10.	1.8	17
22	Immune status is more affected by age than by carotenoid depletion–repletion in healthy human subjects. British Journal of Nutrition, 2012, 108, 2054-2065.	1.2	16
23	A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients. BMC Cancer, 2020, 20, 96.	1.1	15
24	Prognostic Value of Initial Tumor Parameters After Metastatic Relapse. Cancer Investigation, 2011, 29, 635-643.	0.6	14
25	Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer – Preliminary Results From the MENOCOR Study. Clinical Breast Cancer, 2019, 19, e74-e84.	1.1	14
26	Measurement of Residual Disease After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2008, 26, 3094-3094.	0.8	12
27	Combined Methionine Deprivation and Chloroethylnitrosourea Have Time-Dependent Therapeutic Synergy on Melanoma Tumors That NMR Spectroscopy-Based Metabolomics Explains by Methionine and Phospholipid Metabolism Reprogramming. Nutrition and Cancer, 2009, 61, 518-529.	0.9	9
28	Effect of an intensive 3-week preoperative home rehabilitation programme in patients with chronic obstructive pulmonary disease eligible for lung cancer surgery: a multicentre randomised controlled trial. BMJ Open, 2017, 7, e017307.	0.8	9
29	Cystemustine in recurrent high grade glioma. Journal of Neuro-Oncology, 2006, 79, 33-37.	1.4	8
30	Brown Adipose Tissue Activity in Relation to Weight Gain During Chemotherapy in Breast Cancer Patients: A Pilot Study. Nutrition and Cancer, 2014, 66, 1092-1096.	0.9	8
31	Prospective Study on Body Composition, Energy Balance and Biological Factors Changes in Post-menopausal Women with Breast Cancer Receiving Adjuvant Chemotherapy Including Taxanes. Nutrition and Cancer, 2018, 70, 997-1006.	0.9	6
32	Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. BMC Cancer, 2005, 5, 147.	1.1	5
33	Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. International Journal of General Medicine, 2009, 2, 129.	0.8	5
34	Phase I study of [1311] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer, 2022, 22, 417.	1.1	5
35	Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy. Oncology, 2015, 88, 180-188.	0.9	4
36	Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments. Clinical Breast Cancer, 2018, 18, e1093-e1102.	1.1	4

Emilie Thivat

#	Article	IF	CITATIONS
37	Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase Il trial. Anti-Cancer Drugs, 2005, 16, 1003-1007.	0.7	3
38	Does Regional Lymph Node Irradiation Improve the Outcome of NO and pNO Breast Cancer?. Cancer Investigation, 2009, 28, 195-200.	0.6	3
39	Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study. Frontiers in Oncology, 2021, 11, 744609.	1.3	2
40	New Approches in Advanced Melanoma Treated by Nitrosourea. Journal of Immunotherapy, 2004, 27, S52-S53.	1.2	0
41	Abstract 2694: The impact of curcumin plus docetaxel on neuroendocrine features, or not, in castration-resistant prostate cancer: A prospective study. , 2012, , .		0